Dr. Yusra F. Shao, Chief Fellow Hematology and Oncology, Karmanos Cancer Institute, USA on her visit to BSCHH made the following comments while giving her views on our services and how we could reach out more in providing the best of quality care and medical assistance totally free of cost to the less privileged patients suffering from cancer.

Dr. Yusra’s Letter

Yusra F. Shao, MD
7370 Corbett Dr.
Canton, MI 48187

Ms. Zainab Ali Raza Ebrahim
Mr. Jameel Yusuf S.St.
Chairpersons
Bait-ul-Sukoon Cancer Hospital and Hospice
Plot No. S.N.P.A. 17-J, Block –3 K.C.H.S. Union
Karachi Memon Society PECHS
Karachi, Sindh

Dear Ms. Ebrahim and Mr. Yusuf,

I write to you gratefully to have had the opportunity to visit Bait-ul-Sukoon Cancer Hospital on Saturday, December 31st, 2022. I’m a hematology and oncology fellow at Barbara Ann Karmanos Cancer Institute in Detroit, Michigan, USA. My goal for visiting Bait-ul-Sukoon was to understand its infrastructure and identify potential for international collaboration. I first learned about Bait-ul-Sukoon Cancer Hospital during my aunt’s journey with colon cancer. Since then, I had wanted to visit the facility in line with my passion to serve the financially underserved cancer patients in Pakistan.

It is remarkable to see that Bait-ul-Sukoon provides patient-centered care in a professional and healing environment completely free of cost and irrespective of income or faith. During my visit, I was welcomed by Mr. Syed Jafar Ali and Dr. Abdul Qayyum. I found them greatly hospitable and committed to the mission of the hospital. I really appreciate the thoughtfulness in having a
separate hospice ward, on-site laboratory facility, and effort to bring state-of-the-art operating room and imaging resources. This consistent commitment to growth and patient care is most applaudable.

During my visit, we also identified the following avenues of growth through international collaboration: 1. Present grand rounds to Bait-ul-Sulkoon faculty by international experts 2. Provide virtual second opinion for complex oncologic cases 3. Create mechanisms to channel genetic testing and anti-cancer medications such as targeted and immune therapies from the international market. My meeting with the administration was an initial step in actualizing such a collaboration. I am also networking with medical oncologists in the United States who are keen to join this venture. I hope that with ongoing effort, these goals can come to fruition.

I wish Bait-ul-Sukoon’s physicians, staff and administration great success in continuing the work being done and achieving greater feats. I hope to be a committed partner in this growth.

Sincerely,

Yusra F. Shao, MD
Chief Fellow
Hematology and Oncology
Karmanos Cancer Institute
Wayne State University